Switzerland Starts ‘Continuous Review’ of Modern COVID-19 Vaccine

Switzerland has begun an ongoing review of Moderna’s COVID-19 vaccine in order to give it rapid approval if it passes the test in clinical trials, the country’s drug regulator said on Friday. Regulator Swissmedic is already analyzing the progress of the experimental vaccines that are being developed. by AstraZeneca, as well as Pfizer and BioNTech SE in similar ongoing reviews. So-called ongoing reviews allow pharmaceutical companies to submit applications for COVID-19 medicinal products before development work is complete and before supporting documentation is available complete. this week that he has enough data for a first interim analysis of his late-stage COVID-19 vaccine trial, raising hope that initial results will be released soon. more than 90% effective. “Swissmedic can thus obtain an initial picture of the benefit-risk profile of the candidates before the authorization studies are completed,” Swissmedic said in a statement about the ongoing review. This speeds up the review process while preserving the same level of careful control of all requirements related to safety, efficacy and quality. “

As part of the review, Swissmedic said it was working with other drug regulators around the world. Switzerland has already set aside 400 million Swiss francs ($ 437 million) to buy COVID-19 vaccines and has reserved a total of about 16 million. dose of injections. being developed by Moderna, AstraZeneca and Pfizer / BioNTech. ($ 1 = 0.9148 Swiss francs)